Genesis Therapeutics

Genesis Therapeutics is a biotechnology and artificial intelligence (AI) company headquartered in Burlingame, California, with an integrated laboratory in San Diego. The company combines advanced generative and predictive AI models with biotechnology to discover novel small-molecule therapies for serious and treatment-resistant diseases. Genesis accelerates and optimizes drug discovery through its proprietary AI platform, GEMS (Genesis Exploration of Molecular Space).

GEMS is a multilayered platform that integrates deep learning-based predictive models, molecular simulations, and generative AI techniques. The system iteratively generates and tests molecular structures throughout the process from drug candidate design to selection. Components of GEMS include language models for molecule generation, diffusion models for protein-ligand structure prediction, and physics-based machine learning for potency and selectivity estimation. This approach opens new possibilities for drug design against targets classified as “undruggable”.

Research and Technology Areas

Genesis’s research efforts are conducted at the intersection of machine learning, physics, and chemistry. The company’s research team is developing next-generation foundational models capable of understanding the “language” of molecules.

Key research areas include:

• Generative Diffusion Models: Flow-matching and diffusion-based techniques that enable high-fidelity generation of three-dimensional molecular structures.
• Science-Oriented Large Language Models (LLMs): Specialized LLMs that comprehend molecular structures and chemical reactions to generate novel molecules.
• Reinforcement Learning: Directed molecule generation for solving multi-objective optimization problems.
• Multi-Modal Learning: Integration of diverse data types—including 3D structures and biological assay results—to predict pharmacokinetic and toxicity properties.
• Geometric and 3D Deep Learning: Development of equivariant networks that account for the physical symmetries of molecular systems.

Genesis Therapeutics is advancing multiple drug development programs in oncology and immunology using the GEMS platform. The company’s internal pipeline includes drug candidates targeting biological targets that are data-poor or inaccessible to conventional methods. In addition to partnerships initiated with Genentech in 2020 and Eli Lilly in 2022, Genesis has entered multi-target collaboration agreements with Gilead in 2024 and Incyte in 2025. These agreements collectively include upfront payments totaling over $65 million USD.

Funding and Investors

Genesis has raised over $300 million USD in funding from leading technology and biotechnology investors including Andreessen Horowitz, T. Rowe Price, Rock Springs Capital, Fidelity, BlackRock, Radical Ventures, Menlo Ventures, and NVIDIA’s investment arm, NVentures. The 2024 investment and collaboration with NVIDIA have accelerated the development of computational methods and equivariant neural network architectures.

Patents and Scientific Contributions

Genesis holds three core patents in AI-driven drug discovery:

• Computational platform for molecule generation (US12159693B2)
• Chemical computation graphs (US12230367B2)
• Generative machine learning based on textual queries of molecules (US12288600B2)

In addition, Genesis researchers have presented scientific talks on small-molecule discovery, generative modeling, and biomedical AI at events including ICML, the Stanford AI+Biomedicine Seminar, and MIT Tech Talk.

Structure and Organization

The company’s headquarters is in Burlingame, California; its integrated wet laboratory is in San Diego; and its technical center is in New York City. A portion of its workforce operates remotely. The leadership team, led by CEO and co-founder Evan Feinberg, COO Will McCarthy, and CSO Shifeng Pan, includes experts from organizations such as OpenAI, DeepMind, Meta, and Google.